Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Cervical cancer remains a major health burden, particularly in low- and middle-income countries, despite being one of the most preventable cancers. WHO's 90-70-90 targets aim to eliminate cervical cancer globally by 2030. These targets include 90% of girls fully vaccinated with the HPV vaccine by the age of 15 years, 70% of women screened using a high-performance test by the age of 35 years and again by 45 years, and 90% of women with cervical disease receiving appropriate treatment. Achieving these goals requires coordinated national efforts to strengthen health systems, ensure equitable access to care, and integrate cervical cancer control into broader health policies. This review outlines key strategic approaches, including the transition from conventional screening methods to HPV-based screening, the adoption of innovative triage techniques, the implementation of single-dose HPV vaccination, and the integration of primary treatment with palliative care. The strategy places strong emphasis on addressing health inequities, enhancing monitoring systems, and fostering partnerships between governments, non-governmental organizations, and the private sector. With concerted global and national action, the elimination of cervical cancer is not only a possibility but an imminent reality.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411824PMC
http://dx.doi.org/10.1002/ijgo.70276DOI Listing

Publication Analysis

Top Keywords

cervical cancer
20
strategic approaches
8
national action
8
cervical
6
cancer
5
approaches global
4
global cervical
4
cancer elimination
4
elimination update
4
update review
4

Similar Publications

Cervical cancer remains a significant public health issue, ranking as the fourth most common cancer in women globally. In the Netherlands, cervical cancer incidence declined steadily from 1989 to 2001 but increased between 2001 and 2007. This study updates trends in cervical cancer incidence from 1989 to 2023 in the Netherlands and evaluates the impact of screening practices and participation rates in the national population-based screening program.

View Article and Find Full Text PDF

Rationale: Cervical cancer is the fourth most common cancer affecting women worldwide, caused by persistent infection with oncogenic human papillomavirus (HPV) types. While HPV infections usually resolve spontaneously, persistent infections with high-risk HPV types can progress to premalignant glandular or - mostly - squamous intraepithelial lesions, usually classified in cervical intraepithelial neoplasia (CIN). Women with CIN 2 and CIN 3 (i.

View Article and Find Full Text PDF

Cervical cancer continues to pose a significant global health challenge, highlighting the urgent need for accurate and efficient diagnostic techniques. Recent progress in deep learning has demonstrated considerable potential in improving the detection and classification of cervical cancer. This review presents a thorough analysis of deep learning methods utilized for cervical cancer diagnosis, with an emphasis on critical approaches, evaluation metrics, and the ongoing challenges faced in the field.

View Article and Find Full Text PDF

Background: Cervical cancer (CC) is a leading cause of cancer-related deaths worldwide, emphasizing the need for accurate and efficient diagnostic tools. Traditional methods of cervical cell classification are time-consuming and susceptible to human error, highlighting the need for automated solutions.

Materials And Methods: This study introduces the modified hierarchical deep feature fusion (HDFF) method for cervical cell classification using the SIPaKMeD and Herlev datasets.

View Article and Find Full Text PDF

Case Report: Immune-mediated acute liver failure induced by tislelizumab in a patient with advanced cervical cancer.

Front Oncol

August 2025

Hunan Cancer Hospital, The Affiliated Cancer Hospital, Xiangya School of Medicine, Central South University, Changsha, Hunan, China.

Tislelizumab, an anti-PD-1 monoclonal antibody, is associated with immune-related hepatitis in 1.8% of cases, but reports of acute liver failure (ALF) remain exceedingly rare. We present a case of fulminant hepatitis and ALF following Tislelizumab therapy in a 55-year-old woman with locally advanced cervical adenocarcinoma.

View Article and Find Full Text PDF